MedTrace Logo

A Study of rSIFN-co in Subjects With Advanced Solid Tumors

NCT02387307 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-09-27

No results posted yet for this study

Summary

This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell
  • Melanoma
  • Carcinoma, Hepatocellular
  • Colon Cancer

Interventions

DRUG

rSIFN-co

rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.

Sponsors & Collaborators

  • Sichuan Huiyang Life Science and Technology Corporation

    lead INDUSTRY

Principal Investigators

  • David Wai Meng TAI · National Cancer Center Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02387307 on ClinicalTrials.gov